Christoph Pittius is Head of Transactions, AstraZeneca Business Development, and is based in Mölndal, Sweden. He and his team focus on negotiating global strategic in- and out-licensing deals of clinical-stage and on-the-market product opportunities as well as M&A in AstraZeneca’s core indications of interest. Prior to joining AstraZeneca in 2011, Christoph was in senior Business Development roles at Novartis, Boehringer Ingelheim and Hoechst (now Sanofi) in the US and Germany, and also worked at a New York City based Investment Bank. Christoph’s original training was as a biochemist and molecular biologist, obtained at the Max-Planck Institute for Psychiatry, Munich, Germany.